Answers are grounded in this paper and cite their sources.
Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin‐17A (IL‐17A), has been shown to have significant efficacy in the treatment of moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis. Blocking critical mediators of immunity may carry a risk of increased opportunistic infections. Here we present clinical and in vitro findings examining the effect of secukinumab on Mycobacterium tuberculosis infection. We re‐assessed the effect of secukinumab on the incidence of acute tuberculosis (TB) and reactivation of latent TB infection (LTBI) in pooled safety data from five randomized, double‐blind, placebo‐controlled, phase 3 clinical trials in subjects with moderate to severe plaque psoriasis. No cases of TB were observed after 1 year. Importantly, in subjects with a history of pulmonary TB (but negative for interferon‐γ release and receiving no anti‐TB medication) or positive for latent TB (screened by interferon‐γ release assay and receiving anti‐TB medication), no cases of active TB were reported. Moreover, an in vitro study examined the effect of the anti‐tumor necrosis factor‐α (TNFα) antibody adalimumab and secukinumab on dormant M. tuberculosis H37Rv in a novel human three‐dimensional microgranuloma model. Auramine‐O, Nile red staining and rifampicin resistance of M. tuberculosis were measured. In vitro, anti‐TNFα treatment showed increased staining for Auramine‐O, decreased Nile red staining and decreased rifampicin resistance, indicative of mycobacterial reactivation. In contrast, secukinumab treatment was comparable to control indicating a lack of effect on M. tuberculosis dormancy. To date, clinical and preclinical investigations with secukinumab found no evidence of increased M. tuberculosis infections.
No takes yet. Share an insight, caveat, or question.
Kammüller et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: